Close Menu

NEW YORK (GenomeWeb) – Most patients with advanced EGFR-mutant lung cancer also harbor key secondary mutations within their tumors, according to a new study.

Rather than focus on single gene mutations that might be driving lung cancer, researchers from the University of California, San Francisco, examined whether additional oncogene mutations might occur alongside ones in EGFR and affect patient outcomes.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.